Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights


November 05, 2020

- Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy -

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) --  Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter 2020 and recent business highlights.

“We made important progress across the business in the third quarter, including securing significant funding through multiple financings culminating with our IPO, continuing to attract exceptional leaders to Dyne with expertise in muscle and rare diseases, and generating platform-validating preclinical data that is creating momentum for our pipeline,” said Joshua Brumm, president and chief executive officer of Dyne. “We expect we have the cash resources to support our planned IND submissions for our three programs between the fourth quarter of 2021 and the fourth quarter of 2022, and to achieve proof-of-concept data for two of those – our myotonic dystrophy type 1 and Duchenne muscular dystrophy programs. Following this exciting third quarter, Dyne is well positioned to pursue our goal of becoming the world’s leading muscle disease company.”

Recent Highlights

Third Quarter 2020 Financial Results

Cash and cash equivalents: Cash and cash equivalents were $379.6 million as of September 30, 2020 compared to $14.6 million as of December 31, 2019.

Research and development (R&D) expenses: R&D expenses were $9.7 million for the third quarter 2020 compared to $3.0 million for the third quarter of 2019.

General and administrative (G&A) expenses: G&A expenses were $3.8 million during the third quarter of 2020 compared to $0.6 million for the third quarter of 2019.

Net loss: Net loss was $13.9 million or $2.01 per common share for the third quarter 2020 compared to $5.9 million, or $2.36 per common share for the third quarter 2019.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit www.dyne-tx.com, and follow us on TwitterLinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects, plans, objectives of management, the expected timeline for submitting investigational new drug applications and achieving proof-of-concept data readouts and the sufficiency of its cash resources, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and Dyne’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; Dyne’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on Dyne’s business and operations; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

Dyne Therapeutics, Inc.
Condensed Statement of Operations (Unaudited)
(in thousands, except share and per share data)
                 
    Three Months Ended
September 30,
  Nine Months Ended
September 30,
      2020       2019       2020       2019  
Operating expenses:                
Research and development   $ 9,679     $ 2,982     $ 23,102     $ 6,781  
General and administrative     3,841       647       6,945           1,575  
Total operating expenses     13,520       3,629       30,047       8,356  
Loss from operations     (13,520 )     (3,629 )     (30,047 )     (8,356 )
Other (expense) income     (400 )     (2,242 )     (741 )     (1,100 )
Net loss   $ (13,920 )   $ (5,871 )   $ (30,788 )   $    (9,456 )
Net loss per share—basic and diluted   $ (2.01 )   $    (2.36 )   $    (7.51 )   $    (3.94 )
Weighted-average common shares outstanding used in net
loss per share—basic and diluted
    6,920,008       2,491,487       4,100,504       2,401,039  

Dyne Therapeutics, Inc.
Condensed Balance Sheet Data (Unaudited)
(in thousands)
         
    September 30,   December 31,
      2020     2019
Assets        
Cash and cash equivalents   $ 379,606   $ 14,632
Other assets                        1,866                       1,804
Total assets   $ 381,472   $ 16,436
Liabilities and Stockholders’ Equity        
Liabilities                      14,627                      2,400
Stockholders’ equity                    366,845                     14,036
Total liabilities and stockholders’ equity   $ 381,472   $ 16,436


« back to news page